Alnylam Pharmaceuticals
Develops and commercializes RNAi medicines led by the AMVUTTRA-centered TTR franchise.
Something off on this page? Send us feedback.
Profile
Develops RNAi medicines through a delivery platform spanning lipid nanoparticles and subcutaneous GalNAc conjugates. Directly commercialized products include AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, while partners sell Leqvio and Qfitlia; commercial results increasingly depend on AMVUTTRA and the TTR franchise.
Develops and commercializes RNA-interference medicines that silence disease-linked messenger RNA. Direct products include AMVUTTRA and ONPATTRO in transthyretin amyloidosis, alongside GIVLAARI and OXLUMO for rare diseases; Leqvio and Qfitlia are commercialized by partners.
Builds its pipeline around delivery chemistry. Lipid nanoparticles enabled intravenous ONPATTRO, while subcutaneous GalNAc conjugates became the main architecture for durable dosing and support AMVUTTRA's quarterly administration. Newer ESC+ and C16 designs seek to reach additional tissues.
Depends increasingly on AMVUTTRA and the TTR franchise after cardiomyopathy approval widened its market and the newer therapy displaced ONPATTRO commercially. Product growth still rests on regulatory approvals and clinical benefit-risk evidence; the revusiran termination remains the clearest example of that development dependency.
Company facts
Key statistics
Year to date −40.8% · Average volume (30d) 2.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Jefferies | Target | $205 | $230 | ||
| Aug 25, 2026 | Bernstein | Reiterate | Outperform | $447 | $376 | |
| Aug 18, 2026 | BMO Capital | Initiate | Outperform | $470 | $318 | |
| Aug 14, 2026 | Wells Fargo | Reiterate | Equal Weight | $376 | $256 | |
| Aug 4, 2026 | H.C. Wainwright | Target | $485 | $455 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $1.63 | $1.21 | −25.8% | $1.32B | $1.29B | −2.4% | −28.31% |
| Apr 30, 2026Q1 FY26 | $0.87 | $1.51 | +73.2% | $1.12B | $1.17B | +4.6% | −4.32% |
| Feb 12, 2026Q4 FY25 | $1.16 | $0.82 | −29.3% | $1.15B | $1.10B | −4.5% | +1.92% |
| Oct 30, 2025Q3 FY25 | $0.56 | $2.90 | +416.9% | $959.4M | $1.25B | +30.2% | +1.44% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $594.2M | $773.7M | $1.25B | $1.10B | $1.17B | $1.29B | |
| Gross profit | $523.1M | $630.7M | $1.05B | $829.3M | $956.1M | $992.7M | |
| Operating income | $18.1M | −$16.2M | $368.0M | $131.7M | $268.6M | $231.4M | |
| Net income | −$57.5M | −$66.3M | $251.1M | $186.4M | $206.0M | $164.5M | |
| Diluted EPS | −$0.44 | −$0.51 | $1.84 | $1.37 | $1.51 | $1.20 | |
| Gross margin | 88.0% | 81.5% | 84.2% | 75.6% | 81.9% | 76.9% | |
| Operating margin | 3.0% | -2.1% | 29.5% | 12.0% | 23.0% | 17.9% |
Fiscal years (4-quarter sums)FY21 $844.3M · FY22 $1.04B · FY23 $1.83B · FY24 $2.25B · FY25 $3.71B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $3.31B · Total debt $1.27B · Total assets $5.56B · Shareholders' equity $1.35B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 133.81M · Float 133.23M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.02M | 11.23% | 13F | Aug 13, 2026 |
| Capital World Investors | 11.14M | 8.33% | 13F | Aug 12, 2026 |
| BlackRock, Inc. | 10.91M | 8.15% | 13F | Aug 7, 2026 |
| Capital Research Global Investors | 9.75M | 7.29% | 13F | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 6.54M | 4.89% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 1, 2026 | David E. I. Pyott | director | −3,830 | $299.18 |
| Apr 6, 2026 | Melissa McLaughlin | officer: Chief Human Resources Officer | −2,286 | $330.42 |
| Apr 2, 2026 | Melissa McLaughlin | officer: Chief Human Resources Officer | −1,624 | $319.59 |
| Mar 5, 2026 | Kevin Joseph Fitzgerald | officer: CSO & EVP, Head of Research | −658 | $323.98 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | officer: CSO & EVP, Head of Research | −633 | $323.08 |
Peers
- Pfizer
Established oral TTR stabilizer franchise in ATTR cardiomyopathy
- BridgeBio Pharma
Oral Attruby challenger in the core ATTR cardiomyopathy market
- Ionis Pharmaceuticals
Antisense TTR silencing and a broad RNA-targeted drug platform
- Novo Nordisk (ADR)
Competing RNAi medicine for primary hyperoxaluria type 1
- Intellia Therapeutics
One-time CRISPR candidate targeting both major ATTR manifestations
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | $240.00 | +1.22% | $31.73B | 40.1 | 26.7 | 6.6 | +66.9% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| BridgeBio Pharma | $76.60 | +0.03% | $15.00B | — | — | 21.7 | +120.4% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| Median | 24.1 | 14.2 | 11.6 | +0.0% |